Silvano Spinelli

Chairman at Alia Therapeutics

Silvano founded EOS S.p.A. (Ethical Oncology Science) in January 2006 and has been its Chairman and CEO until the company was acquired by Clovis Oncology in November 2013 for 470 million US Dollars. Previously Silvano was co-founder and CEO of Novuspharma. The company has its IPO in 2000 in the Italian Nuovo Mercato, collecting more than 160 million Euro. Novuspharma was acquired by Cell Therapeutics in 2003. Silvano was previously Head of R&D at Boehringer Mannheim Italia. He holds a degree in Organic Chemistry obtained at the University of Pisa.